Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

计划入组 12 人 · 首次发布于 2025 年 9 月 10 日

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

计划入组 20 人 · 首次发布于 2017 年 7 月 2 日

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

计划入组 100 人 · 首次发布于 2019 年 12 月 4 日

anti-CD19/CD20 CAR-T

Anti-CD19-CD20 CAR T Cells

Mister Car Wash

United States

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

Bispecific CAR-T Therapy Targeting CD19/CD20 Shows Promise in Relapsed B-Cell Lymphoma

Kite Highlights CAR T-cell Therapy Portfolio with Positive Survival Outcomes at ASH 2024

Johnson & Johnson's Dual-Targeting CAR-T Therapy Achieves 80% Complete Response Rate in Lymphoma Trial